vimarsana.com

Page 24 - லிநேபேர்கேற் விரிவான புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Clinical Challenge: HER2-Positive Breast Cancer in Older Women

Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study

Trodelvy More than Doubled Overall Survival as Second-Line Treatment in New ASCENT Subgroup Analysis – Gilead Sciences, Inc. today announced new data from the Phase 3 ASCENT study evaluating Trodelvy ® in relapsed or refractory metastatic triple-negative breast cancer . In this subgroup analysis of brain metastases-negative patients who received only one line of prior systemic therapy in the metastatic setting in .

Researchers discover gene that impacts the development of Ewing sarcoma in children

Researchers discover gene that impacts the development of Ewing sarcoma in children Researchers have discovered a gene, OTUD7A, that impacts the development of Ewing sarcoma, a bone cancer that occurs mainly in children. They have also identified a compound that shows potential to block OTUD7A protein activity. The finding, by scientists at the University of North Carolina and the Lineberger Comprehensive Cancer Center, appeared online June 1, 2021, in Advanced Science. About 250 children and young adults are diagnosed with Ewing sarcoma each year in the U.S. About half of those diagnosed will ultimately succumb to the disease, pointing to the need for better therapies.

Researchers discover gene linked to bone cancer in children, ID potential novel therapy

UNC Lineberger researchers have discovered a gene, OTUD7A, that impacts the development of Ewing sarcoma, a bone cancer that occurs mainly in children. They have also identified a compound that shows potential to block OTUD7A protein activity. Critical relationships between proteins contribute to the development of cancers such as Ewing sarcoma. So, it was a seminal discovery when the UNC researchers found that OTUD7A controls the cancer-causing fusion protein.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.